• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum.

作者信息

Silva Miguel, Calçada Carla, Teixeira Miguel, Veiga Maria Isabel, Ferreira Pedro Eduardo

机构信息

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga 4710-057, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Braga, Portugal.

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga 4710-057, Portugal; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Braga, Portugal.

出版信息

Lancet Infect Dis. 2020 Jan;20(1):26-27. doi: 10.1016/S1473-3099(19)30689-9.

DOI:10.1016/S1473-3099(19)30689-9
PMID:31876497
Abstract
摘要

相似文献

1
Multigenic architecture of piperaquine resistance trait in Plasmodium falciparum.恶性疟原虫对哌喹耐药性状的多基因结构
Lancet Infect Dis. 2020 Jan;20(1):26-27. doi: 10.1016/S1473-3099(19)30689-9.
2
Plasmodium falciparum resistance to piperaquine driven by PfCRT.由恶性疟原虫氯喹抗性转运蛋白（PfCRT）驱动的恶性疟原虫对哌喹的抗性。
Lancet Infect Dis. 2019 Nov;19(11):1168-1169. doi: 10.1016/S1473-3099(19)30543-2.
3
Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.越南中南部宁顺省福川乡恶性疟原虫对青蒿素类药物的敏感性和间日疟原虫对氯喹的敏感性。
Malar J. 2019 Jan 17;18(1):10. doi: 10.1186/s12936-019-2640-2.
4
[In vitro sensitivity of Plasmodium falciparum isolates from China-Myanmar border region to chloroquine, piperaquine and pyronaridine].[中国-缅甸边境地区恶性疟原虫分离株对氯喹、哌喹和咯萘啶的体外敏感性]
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2012 Feb 29;30(1):41-4.
5
Plasmodium falciparum Resistance to Artemisinin Derivatives and Piperaquine: A Major Challenge for Malaria Elimination in Cambodia.恶性疟原虫对青蒿素衍生物和哌喹的耐药性：柬埔寨疟疾消除面临的重大挑战。
Am J Trop Med Hyg. 2016 Dec 7;95(6):1228-1238. doi: 10.4269/ajtmh.16-0234. Epub 2016 Oct 17.
6
New genetic marker for piperaquine resistance in Plasmodium falciparum.恶性疟原虫对哌喹耐药性的新遗传标记
Lancet Infect Dis. 2017 Feb;17(2):119-121. doi: 10.1016/S1473-3099(16)30414-5. Epub 2016 Nov 3.
7
Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia.耐多药恶性疟原虫的加速进化与传播致使东南亚最新的一线抗疟药物失效。
Lancet Infect Dis. 2019 Sep;19(9):916-917. doi: 10.1016/S1473-3099(19)30394-9. Epub 2019 Jul 22.
8
CHLOROQUINE-RESISTANT FALCIPARUM MALARIA IN SOUTH-EAST ASIA, WITH A REPORT OF A CASE FROM THAILAND.东南亚的氯喹耐药恶性疟，附泰国一例报告。
J R Army Med Corps. 1964;110:172-4.
9
[In vitro sensitivity of Plasmodium falciparum to chloroquine, piperaquine, pyronaridine and artesunate in Yuxi prefecture of Yunnan province].云南省玉溪市恶性疟原虫对氯喹、哌喹、咯萘啶和青蒿琥酯的体外敏感性
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 1998;16(6):460-2.
10
Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.在布基纳法索，阿莫地喹联合磺胺多辛-乙胺嘧啶、蒿甲醚-本芴醇以及双氢青蒿素-哌喹治疗无并发症恶性疟原虫疟疾的随机对照研究
Clin Infect Dis. 2007 Dec 1;45(11):1453-61. doi: 10.1086/522985. Epub 2007 Oct 22.

引用本文的文献

1
Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa.撒哈拉以南非洲疟疾感染人群中恶性疟原虫K13基因对青蒿素联合疗法及相关药物的新出现突变
Parasites Hosts Dis. 2025 May;63(2):109-122. doi: 10.3347/PHD.24053. Epub 2025 May 26.
2
Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections.蒿甲醚-本芴醇治疗在非洲疟疾感染中选择了恶性疟原虫多药耐药性1（pfmdr1）拷贝数增加的情况。
J Infect Dis. 2025 Jul 11;231(6):e1119-e1128. doi: 10.1093/infdis/jiaf155.
3
Decreased dihydroartemisinin-piperaquine protection against recurrent malaria associated with Plasmodium falciparum plasmepsin 3 copy number variation in Africa.
在非洲，双氢青蒿素-哌喹对复发性疟疾的保护作用降低与恶性疟原虫天冬氨酸蛋白酶3拷贝数变异有关。
Nat Commun. 2025 Mar 18;16(1):2680. doi: 10.1038/s41467-025-57726-5.
4
Genetic surveillance shows spread of ACT resistance during period of malaria decline in Vietnam (2018-2020).基因监测显示，在越南疟疾发病率下降期间（2018 - 2020年），青蒿素联合疗法（ACT）耐药性出现了传播。
Front Genet. 2024 Dec 2;15:1478706. doi: 10.3389/fgene.2024.1478706. eCollection 2024.
5
Evolution of genetic markers for drug resistance after the introduction of dihydroartemisinin-piperaquine as first-line anti-malarial treatment for uncomplicated falciparum malaria in Indonesia.在印度尼西亚将双氢青蒿素-哌喹作为治疗无并发症恶性疟的一线抗疟治疗药物引入后，耐药性遗传标记的演变。
Malar J. 2023 Aug 9;22(1):231. doi: 10.1186/s12936-023-04658-4.
6
Plasmodium falciparum resistance to artemisinin-based combination therapies.恶性疟原虫对青蒿素类复方疗法的抗药性。
Curr Opin Microbiol. 2022 Oct;69:102193. doi: 10.1016/j.mib.2022.102193. Epub 2022 Aug 22.
7
Drug Resistance Genes and Co-Expression During Artemether-Lumefantrine Therapy.蒿甲醚-本芴醇治疗期间的耐药基因与共表达
Front Pharmacol. 2022 May 24;13:868723. doi: 10.3389/fphar.2022.868723. eCollection 2022.
8
A single point mutation in the Plasmodium falciparum 3'-5' exonuclease does not alter piperaquine susceptibility.恶性疟原虫3'-5'核酸外切酶中的单点突变不会改变对哌喹的敏感性。
Malar J. 2022 Apr 22;21(1):130. doi: 10.1186/s12936-022-04148-z.
9
Plasmodium falciparum resistance to ACTs: Emergence, mechanisms, and outlook.恶性疟原虫对青蒿素类复方药物的抗药性：出现、机制和展望。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:102-118. doi: 10.1016/j.ijpddr.2021.05.007. Epub 2021 May 26.
10
Modulation of Triple Artemisinin-Based Combination Therapy Pharmacodynamics by Genotype.基因型对基于青蒿素的三联联合疗法药效学的调节作用
ACS Pharmacol Transl Sci. 2020 Nov 2;3(6):1144-1157. doi: 10.1021/acsptsci.0c00110. eCollection 2020 Dec 11.